"People actually talk these days about a potential return to the "pre-antibiotic era" where we no longer have effective tools to treat serious infectious disease. Clearly, we must encourage more judicious use of these important drugs through improved infection control, rational prescribing and better patient compliance. But even if we improve these practices, resistant bacteria will continue to develop. No matter what, we need new and better drugs…and we need them now. Yet the R & D pipeline is distressingly low..."
--Margaret A. Hamburg, M.D.
Commissioner, U.S. Food and Drugs Administration (FDA)
National Press Club Luncheon, October 6, 2010.
Antibiotic-resistant bacteria, also known as "superbugs," pose a significant threat to public health. New antibiotics are not being developed...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|